WALD icon

Waldencast

1.81 USD
+0.02
1.12%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
1.75
-0.06
3.31%
1 day
1.12%
5 days
4.02%
1 month
-3.72%
3 months
-20.61%
6 months
-42.36%
Year to date
-51.6%
1 year
-55.85%
5 years
-81.62%
10 years
-81.62%
 

About: Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

Employees: 332

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

1.24% more ownership

Funds ownership: 19.59% [Q1] → 20.82% (+1.24%) [Q2]

4% less funds holding

Funds holding: 56 [Q1] → 54 (-2) [Q2]

14% less capital invested

Capital invested by funds: $65.8M [Q1] → $56.9M (-$8.95M) [Q2]

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$3
66% upside
Avg. target
$3
66% upside
High target
$3
66% upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Telsey Advisory Group
Dana Telsey
$3
Outperform
Maintained
20 Aug 2025

Financial journalist opinion

Based on 3 articles about WALD published over the past 30 days

Neutral
GlobeNewsWire
3 days ago
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
Neutral
GlobeNewsWire
26 days ago
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S.
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
Neutral
Benzinga
26 days ago
Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Waldencast plc WALD will release earnings results for the second quarter after the closing bell on Monday, Aug. 18.
Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Neutral
GlobeNewsWire
1 month ago
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a market projected to be $2.2 billion by 2029, into the growing U.S. dermal filler market, projected to reach $2 billion in market size by 2029, effectively doubling its addressable market.1 The move marks a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions.
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Neutral
Seeking Alpha
3 months ago
Waldencast: Learning To Grow Hurts Sometimes
Waldencast is a fast-growing beauty company with strong brands (Milk Makeup, Obagi), but faces margin pressure and negative earnings due to high SG&A and debt. Recent revenue growth remains solid, but Q1 FY25 saw a sales dip, especially in Milk Makeup, due to international headwinds and inventory adjustments. The company's financials are typical for a high-growth firm: negative cash flow, high leverage, but manageable liquidity, and a long debt runway until 2030.
Waldencast: Learning To Grow Hurts Sometimes
Neutral
Seeking Alpha
4 months ago
Waldencast plc (WALD) Q1 2025 Earnings Call Transcript
Waldencast plc (NASDAQ:WALD ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Allison Malkin - Partner ICR, Investor Relations Michel Brousset - Founder & Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants John Chapman - Alliance Global Partners Jonna Kim - TD Cowen Operator Good day, and welcome to the Waldencast First Quarter 2025 Earnings Call. All participants will be in listen-only mode.
Waldencast plc (WALD) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
Waldencast Reports Q1 2025 Financial Results
Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA
Waldencast Reports Q1 2025 Financial Results
Neutral
GlobeNewsWire
4 months ago
Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast
LONDON, May 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its First Quarter Fiscal 2025 conference call and webcast. As previously announced, the Company will issue its First Quarter Fiscal 2025 results on May 13, 2025 after the close of the U.S. market.
Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast
Neutral
GlobeNewsWire
4 months ago
Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream
A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion
Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream
Neutral
Seeking Alpha
5 months ago
Waldencast plc (WALD) Q4 2024 Earnings Call Transcript
Waldencast plc (NASDAQ:WALD ) Q4 2024 Earnings Conference Call March 19, 2025 8:30 AM ET Company Participants Allison Malkin - Investor Relations Michel Brousset - Founder and Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants Jonna Kim - TD Cowen Ashley Helgans - Jefferies Linda Bolton Weiser - D.A. Davidson Olivia Tong - Raymond James Operator Greetings, welcome to the Waldencast Fourth Quarter and Fiscal Year 2024 Earnings Call.
Waldencast plc (WALD) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™